Bayer Faces a Split Verdict: Pipeline Progress Meets a Profit Test It Hasn't Passed

Bayer investors are being asked to weigh two very different kinds of news against each other. On one side sit regulatory and clinical milestones in the pharmaceutical pipeline. On the other sits the harder, less forgiving question of whether the existing business can turn revenue into profit. The two do not move in lockstep, and the market's next real answer arrives on 3 November 2026, when Bayer publishes its third-quarter report.

JPMorgan kept Bayer at "Overweight" on Friday, but analyst Richard Vosser's numbers carried a warning. He expects revenue to come in 2% above consensus, while EBITDA lands 6% below it. His price target stands at EUR 61. That combination — top-line strength paired with bottom-line weakness — frames the central issue. Beating on sales alone would not prove much. What matters is whether Bayer can convert extra revenue into a durable operating result. Vossers' view is a forecast, not a reported figure; the quarterly statement will show whether the gap he anticipates actually materialises.

Three announcements, three different finish lines

The pharmaceutical headlines of recent weeks are easy to lump together, but they represent distinct stages of progress rather than a single success story. Roughly two weeks ago, the FDA accepted Bayer's supplemental application for Kerendia (finerenone) in adults with chronic kidney disease without diabetes. The filing rests on data from the Phase III FIND-CKD trial. Acceptance opens the door to review; it is not an approval, and the distinction matters more than the headline label of "progress."

Separately, Bayer's wholly owned subsidiary Vividion Therapeutics dosed its first patient in a global Phase II study on Thursday. The trial examines VVD-214 in combination with pembrolizumab as a first-line treatment for advanced MSI-high or dMMR colorectal cancer, comparing the combination against pembrolizumab alone to test whether the pairing adds benefit. Here the milestone is the start of treatment within the study — not its result. Finerenon and the Vividion programme should not be read as equally advanced.

A third thread runs in a different direction entirely. Bayer announced a USD 2.2 billion investment in a new pharmaceutical production site in New Albany, Ohio. That is a declared investment aimed at manufacturing, not a study readout or a regulatory decision. Its size does not substitute for either.

Where the risk actually sits

The optimistic case combines firmer operating results with continued pipeline momentum, each reinforcing the other. The pessimistic case confirms Vosser's expected EBITDA shortfall — and in that scenario, even stronger sales would struggle to dispel doubts about earnings quality. Neither the start of patient dosing nor the acceptance of a filing offers a guaranteed offset. A first patient enrolled is no proof of efficacy, and a filing under review is not a positive approval decision.

That leaves investors with a timing and economic gap: research and regulatory advances can support expectations while the next earnings report has yet to back them up operationally. Until the medical projects deliver and the operating line holds, the weighting between the two will stay unsettled.

The calendar sets the next checkpoint

Bayer will release its Q3 2026 statement at 7:30 CET on 3 November, with a media update following at 10:00 CET. That date is the next firmly scheduled reference point for judging the business on economic terms. Ahead of it, the pipeline news is best sorted by status — a regulatory step, the opening of a clinical treatment phase, and a production plan — rather than treated as a uniform short-term earnings driver. The separation between a development milestone and a financial result remains the thing to watch.